Sona Nanotech sees 80% response in cancer study

Executive Summary

• Sona Nanotech Inc. reported an 80% response rate in its first-in-human clinical study for its Targeted Hyperthermia Therapy (THT) in patients with immunotherapy-resistant cutaneous metastatic melanoma.
• The study involved 10 advanced-stage patients who had failed standard immunotherapy; 8 out of 10 showed significant clinical response, with 6 showing no detectable residual melanoma in biopsied tumors.
• The company is preparing for a Canadian clinical trial, having already received research ethics board approval and submitted an Investigational Testing Authorization (ITA) application to Health Canada.

Key Details

• Study Population: 10 patients with histologically confirmed, immunotherapy-resistant cutaneous metastatic melanoma.
• Treatment Protocol: Patients received up to four tumors treated with THT on days one and eight of the study.
• Efficacy Results:
  • 8 out of 10 patients (80%) experienced a significant clinical response by day 15.
  • 6 out of the 8 responding patients showed no detectable residual melanoma in representative, biopsied tumors (complete response).
  • 2 patients showed no response.
  • Responses were confirmed after only two weeks from initial treatment.
• Safety Profile:
  • One stage IV patient reported a serious adverse event unrelated to THT, which resolved.
  • Two stage IV patients expired shortly after the study period due to distant disease progression.
• Operational Feedback: Significant data was captured regarding clinician and patient experience to improve the physical delivery and design of THT for future studies.
• Management Change: Chief Scientific Officer Dr. Len Pagliaro is stepping back from an operational role to join the board of directors, citing the fulfillment of his 16-year vision with these results.
• Next Steps: An investor webinar is scheduled for Monday, Oct. 20, at noon ET to discuss results and future plans.

Notable Quotes

• David Regan, CEO: "These favourable results -- demonstrated in the majority of treated patients -- show that Sona's THT therapy has successfully eliminated melanoma in tumours where leading treatments had previously failed. This outcome has exceeded our expectations and delivered on our commitment to investors to produce human efficacy data quickly."
• Dr. Carlos Rojas, Principal Investigator: "We were very impressed by the rapid and measurable responses observed in patients who had exhausted standard immunotherapy options. These outcomes have provided meaningful hope for the patients enrolled."
• Dr. Carman Giacomantonio, CMO: "Although this study was not powered to determine response rates, eight out of 10 patients experienced responses in a treated tumour with six out of those eight patients' biopsied tumours showing a complete response -- commands one's attention. Equally impressive is the observation that these responses were confirmed after only two weeks from the initial treatment. This, to my knowledge, is unprecedented."